Various reports have shown that cannabinoids
(the active components of marijuana and their derivatives) can reduce
tumour growth and progression in animal models of cancer, in addition to
their well-known palliative effects on some cancer-associated symptoms.
This Opinion article discusses our current understanding of cannabinoids
as antitumour agents, focusing on recent insights into the molecular
mechanisms of action, including emerging resistance mechanisms and
opportunities for combination therapy approaches. Such knowledge is
required for the optimization of preclinical cannabinoid
-based therapies and for the preliminary clinical testing that is currently underway.
Medicinal Genomics: http://www.medicinalgenomics.com/wp-content/uploads/2011/07/Towards-the-use-of-cannabinoids-as-anti-tumor-agents1.pdf